9-Aug-21 - First patient dosed
+9 months
27-May-22 - 6th patient dosed (trial advances to P2)
+5-8 months
Q4-22 - 10th patient dosed (Borje's options vest)
+7-9 months
7-Jul-23 - 20th patient dosed
"Given the strategic intent of the Company to migrate from RC110 to RC220, and with the full endorsement of Professor Nagler, it has been agreed that the RI-002 protocol will recruit the final two patients and then proceed to report on outcomes over the coming months.
...The Chaim Sheba investigational team is now working towards assembling the data for publication in a peer-reviewed journal followed by a report to the market on the study outcomes."
They were recruiting >1 patient a month once they hit P2 (probably easy to recruit given interim results detailed in ASH publication). Should have long recruited the final 2 patients.
T believes it to be commercially negligent releasing the Cardio MOA - could feel the same about any validation of CPACS / FTO inhibition. IMO holders should be fully informed of all matters CPACS/FTO prior to the expiry of the bonus options - whether that's detrimental to the future IP value or otherwise.
9-Aug-21 - First patient dosed+9 months27-May-22 - 6th patient...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |